Opinion|Videos|August 7, 2024
Guidelines & FDA Approval of Novel Friedreich Ataxia Therapy
A key opinion leader examines the November 2022 guidelines for managing Friedreich's ataxia, discusses the first FDA-approved therapy for the condition, and explains how this treatment is integrated into current disease management strategies.
Advertisement
Episodes in this series
- What are some of the key recommendations outlined in the guidelines for managing FA published in November 2022?
- Could you elaborate on the significance of omaveloxolone as the first FDA-approved therapy for Friedreich’s ataxia and how you incorporate this treatment into your disease management regimen? Since the approval of omaveloxolone, what has been the impact on the management of advanced stages of the disease and life expectancy in FA patients?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Highlighting Gaps in Allergic Rhinitis Care, Allergen Immunotherapy Access
2
Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD
3
Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma
4
Balancing Innovation With Administrative Burdens in Cancer Care
5
